Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the large outcome trials conducted so far have been mostly based on preprandial glucose and A1C targets, with limited evidence of a long-term benefit of targeting PPG alone (49,50).”
From Targets for Glycemic Control (2018) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, manipulating prandial glucose levels failed to impact clinical outcome, and therefore, this remains an unresolved area.142,143”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin treatment plans targeting postprandial glucose compared with those targeting preprandial glucose (73).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (21) demonstrated increased mortality with intensive glycemic goals (A1C of 6.4%), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (22) showed similar cardiovascular outcomes wi…”
InfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study (18), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.”
ResultStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Cited by
Items 101–200 of 350
Khunti, K., Bellary, S., Karamat, M. A., Patel, K., Patel, V., Jones, A., Gray, J., Shepherd, P., Hanif, W., & the South Asian Health Foundation (2017) · Diabetic Medicine · doi:10.1111/dme.13103 · Cited by 58
Monnier, L., Colette, C., & Owens, D. R. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101225 · Cited by 63
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“Three trials provided non-specific data on HF episodes during follow-up without detailing associated death, hospitalization, or need for escalated HF treatment (25,38,39).”
BackgroundEvaluation of a Remote Monitoring System for Diabetes Control
Katalenich, B., Shi, L., Liu, S., Shao, H., McDuffie, R., Carpio, G., Thethi, T., & Fonseca, V. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.022 · Cited by 56
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
“A caveat of this study, which should be considered, is that the magnitude of the differences in PPG levels between the two treatment regimens was smaller than expected, and the trial was eventually stopped due to lack of efficacy (18).”
BackgroundOhara, M., Nagaike, H., Goto, S., Fukase, A., Tanabe, Y., Tomoyasu, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.017 · Cited by 59
The rise and fall of HbA1c as a risk marker for diabetes complications
Kilpatrick, E. S. (2012) · Diabetologia · doi:10.1007/s00125-012-2610-5 · Cited by 57
“Although postprandial hyperglycaemia (a subset of glucose variability) is generally regarded as a risk marker for cardiovascular disease [5], the only prospective study to specifically assess whether reducing within-day glycaemia might influence cardiovascular events has been unable show any benefit [6].”
BackgroundInsulin and atherosclerosis: How are they related?
Monnier, L., Hanefeld, M., Schnell, O., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.001 · Cited by 66
Mellor, D. D., Madden, L. A., Smith, K. A., Kilpatrick, E. S., & Atkin, S. L. (2012) · Diabetic Medicine · doi:10.1111/dme.12030 · Cited by 59
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 51
For debate.Glucose variability and diabetes complication risk: we need to know the answer
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02929.x · Cited by 57
Peak-time determination of post-meal glucose excursions in insulin-treated diabetic patients
Daenen, S., Sola‐Gazagnes, A., M’Bemba, J., Dorange-Breillard, C., Defer, F., Elgrably, F., Larger, É., & Slama, G. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.12.002 · Cited by 56
Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
Ceriello, A. (2010) · Diabetes Care · doi:10.2337/dc10-0634 · Cited by 49
“However, the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study (18) last year and the NAVIGATOR (1) study now, have failed to confirm this finding.”
BackgroundMethodMosenzon, O., & Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2007 · Cited by 53
Self-citationMcVey, E., Hirsch, L. J., Sutter, D. E., Kapitza, C., Dellweg, S., Clair, J., Rebrin, K., Judge, K., & Pettis, R. J. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600403 · Cited by 54
Mo, Y., Lu, J., & Zhou, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14112 · Cited by 56
“…Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study 72 , no difference in risk for future cardiovascular event rates existed between the prandial insulin group and basal insulin group, although this…”
BackgroundRSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Postprandial Hyperglycemia and Cardiovascular Disease
Ceriello, A. (2009) · Diabetes Care · doi:10.2337/dc08-2209 · Cited by 47
“(1) try to answer a hotly debated question of the last 10 years: is postprandial hyperglycemia an independent risk factor for cardiovascular disease in diabetes? This question, highlighted recently, has arisen because of the identified linear relationship, widely confirmed in many studies, between the risk of cardiova…”
BackgroundMeng, X., Gong, C., Cao, B., Peng, X., Wu, D., Gu, Y., Wei, L., Liang, X., Liu, M., Li, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2879 · Cited by 45
“Excess reactive oxygen species can damage cellular DNA and trigger the activation of polyadenylation diphosphate ribose polymerase, which in turn activates pathways leading to endothelial damage (5).”
BackgroundInfluentialIs there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
“In addition, a study on patients with type 2 diabetes treated with insulin after acute myocardial infarction showed that insulin therapy focusing on postprandial hyperglycemia provided no benefit over insulin treatment with preprandial glucose targets [6].”
BackgroundWang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 46
“Ten studies enrolled diabetic patients with a history of macrovascular disease [9, 10, 34–41], and HEART2D, EXAMIN, and DIGAMI1 only enrolled patients who had recently experienced adverse coronary events.”
BackgroundInitiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents
Bretzel, R. G., Eckhard, M., Landgraf, W., Owens, D. R., & Linn, T. (2009) · Diabetes Care · doi:10.2337/dc09-s319 · Cited by 44
Picconi, F., Flaviani, A. D., Malandrucco, I., Giordani, I., & Frontoni, S. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.03.006 · Cited by 42
Takao, T., Suka, M., Yanagisawa, H., & Iwamoto, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12610 · Cited by 35
Leahy, J. (. L., Aleppo, G., Fonseca, V. A., Garg, S. K., Hirsch, I. B., McCall, A. L., McGill, J. B., & Polonsky, W. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00222 · Cited by 34
“In contrast, the HEART-2D trial compared prandial to basal insulin therapy 21 days after acute myocardial infarctions in persons with T2D and found lower daily mean PPG with prandial insulin, but no associated practical or biological impact on A1c or cardiovascular events [37].”
ResultGiugliano, D., Maiorino, M., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02619.x · Cited by 36
Glycemic Variability: Can We Bridge the Divide Between Controversies?
Monnier, L., & Colette, C. (2011) · Diabetes Care · doi:10.2337/dc11-0071 · Cited by 46
“As the results of the HEART2D trial suggest that glucose variability is not a risk factor for cardiovascular diseases in patients with type 2 diabetes treated with insulin (1,2), several “burning” questions can be raised, why could glucose variability be a risk factor for cardiovascular diseases in patients”
BackgroundMethodInfluentialConget, I., Castañeda, J., Petrovski, G., Guerci, B., Racault, A.-S., Reznik, Y., Cohen, O., Runzis, S., de Portu, S., Aronson, R., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0159 · Cited by 38
Sheu, W. H., Rosman, A., Mithal, A., Chung, N., Lim, Y. T., Deerochanawong, C., Soewondo, P., Lee, M., Yoon, K., & Schnell, O. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.04.019 · Cited by 42
Percutaneous Coronary Interventions in the Diabetic Patient: Where Do We Stand?
Bittl, J. A. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001944 · Cited by 36
Taguchi, K., Hida, M., Matsumoto, T., Ikeuchi-Takahashi, Y., Onishi, H., & Kobayashi, T. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00157 · Cited by 33
Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 38
“…Hyperglycemia and Its Effect After Acute Myocardial In-farction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study 21 and the Nategli-nide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study 22 failed to show beneficial effects of…”
Basal Plus Basal–Bolus Approach in Type 2 Diabetes
Ampudia‐Blasco, F. J., Rossetti, P., & Ascaso, J. F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0001 · Cited by 35
“18 Furthermore, the addition of prandial insulin results in a greater incidence of hypoglycemia, 16,17 even when BI is successfully titrated to obtain comparable A 1C levels.”
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 31
“The Hyperglycemia and its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) study investigated the use of basal or thrice-daily bolus insulin to control FPG or PPG, respectively, in patients with T2DM who had experienced an acute MI.60 As PPG excurs…”
BackgroundResultInfluentialSelf-Monitoring of Blood Glucose: A Prerequisite for Diabetes Management in Outcome Trials
Schnell, O., Hanefeld, M., & Monnier, L. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814528134 · Cited by 39
“5 mmol/l assumed for the power calculations to achieve the primary objective.(22) Undoubtedly, SMBG was a key element in the study, helping to keep HbA1c levels at comparable levels between the 2 groups.”
BackgroundNear normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 30
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 29
Eldor, R., & Raz, I. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.6 · Cited by 36
“These results were augmented by the HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) trial [9] where 1,115 diabetic patients suffering from an acute myocardial infarction, were randomly assigned to prandial or basal insulin an…”
MethodSelf-citationSaisho, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1776262 · Cited by 28
Chittari, M. V., McTernan, P. G., Bawazeer, N. M., Constantinides, K., Ciotola, M., O’Hare, J. P., Kumar, S., & Ceriello, A. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03223.x · Cited by 30
Zenari, L., & Marangoni, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12143 · Cited by 30
“In the HEART2D study, preprandial therapy was not superior to basal insulin for reduction of cardiovascular events in patients with a history of stroke [29].”
MethodInpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis
Iyengar, R., Franzese, J., & Gianchandani, R. Y. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1044-y · Cited by 31
Qi, L., Geng, X., Feng, R.-L., Wu, S., Fu, T., Li, N., Ji, H., Cheng, R., Wu, H., Wu, D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111869 · Cited by 35
Wolffenbuttel, B. H. R., Klaff, L. J., Bhushan, R., Fahrbach, J. L., Jiang, H. H., & Martin, S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02824.x · Cited by 28
Fonda, S. J., Salkind, S. J., Walker, M. S., Chellappa, M., Ehrhardt, N. M., & Vigersky, R. A. (2012) · Diabetes Care · doi:10.2337/dc12-1225 · Cited by 28
Postprandial Glucose: Marker or Risk Factor?
Avogaro, A. (2011) · Diabetes Care · doi:10.2337/dc11-1442 · Cited by 29
“The HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) study concluded that in diabetic survivors of acute myocardial infarction, the treatment of postprandial versus basal glucose led to similar HbA1c levels and no difference i…”
BackgroundDiabetes, Cardiovascular Risk and Nephropathy
Hahr, A. J., & Molitch, M. E. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.006 · Cited by 29
Leonardi, S., Armstrong, P. W., Schulte, P. J., Ohman, E. M., & Newby, L. K. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht003 · Cited by 26
Kitano, D., Chiku, M., Li, Y., Okumura, Y., Fukamachi, D., Takayama, T., Hiro, T., Saito, S., & Hirayama, A. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-92 · Cited by 28
“However, several studies have shown that PPHG, more than impaired fasting glucose, is related to endothelial dysfunction and cardiovascular risk [4,34-39].”
BackgroundPrognostic significance of glycemic variability after cardiac surgery
Bansal, B., Carvalho, P., Mehta, Y. B., Yadav, J., Sharma, P., Mithal, A., & Trehan, N. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.02.010 · Cited by 30
“Its role in increasing cardiovascular complications has been questioned after the negative results in HEART2D trial (Raz et al., 2009).”
BackgroundAlam, M. S., Aqil, M., Qadry, S. A. S., Kapur, P., & Pillai, K. K. (2014) · Pharmacology & Pharmacy · doi:10.4236/pp.2014.57073 · Cited by 37
Price, H. I., Agnew, M. D., & Gamble, J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006341 · Cited by 25
Glycemic Variability: Looking Beyond the A1C
Tylee, T. S., & Trence, D. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.149 · Cited by 28
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Practical approaches for self-monitoring of blood glucose: an Asia-Pacific perspective
Chowdhury, S., Ji, L., Suwanwalaikorn, S., Yu, N.-C., & Tan, E. K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1005832 · Cited by 27
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 27
“Similar levels of HbA1c were achieved in the two groups, differences for fasting glucose were obtained while the differences in post-prandial glucose were lower than expected, the risk of future cardiovascular events was not significantly different.(33) Nevertheless, a post-hoc analysis showed that this risk was signi…”
ResultIncretin-based therapies: new treatments for type 2 diabetes in the new millennium
Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 25
“5%,(9) and that PPG increases cardiovascular risk.(10,11) However, no current”
Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes
Tsuchiya, T., Saisho, Y., Murakami, R., Watanabe, Y., Inaishi, J., & Itoh, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0012 · Cited by 23
“More‐ over, interventions aiming to reduce postprandial glyce‐ mic excursion have failed to show improvement of CV outcomes [22-24].”
BackgroundGiorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
“The HEART2D study failed to show any effect on CV risk of lowering PPG by administration of prandial insulin [68].”
BackgroundYamamoto, K., Ito, T., Nagasato, T., Shinnakasu, A., Kurano, M., Arimura, A., Arimura, H., Hashiguchi, H., Deguchi, T., Maruyama, I., et al. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0206-8 · Cited by 22
Khaire, S. S., Gada, J. V., Utpat, K. V., Shah, N., Varthakavi, P. K., & Bhagwat, N. M. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00098-0 · Cited by 20
Glucose lowering effect of montbretin A in Zucker Diabetic Fatty rats
Yuen, V. G., Coleman, J. E., Withers, S. G., Andersen, R. J., Brayer, G. D., Mustafa, S., & McNeill, J. H. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2599-4 · Cited by 21
“on oxidative stress [24–26], studies with acarbose show little or no effect on oxidative stress levels [27, 28].”
BackgroundAlwani, A. A., Kaur, R., Bairwa, M. L., Misra, P., & Nongkynrih, B. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00203-7 · Cited by 30
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 24
Takao, T., Takahashi, K., Suka, M., Suzuki, N., & Yanagisawa, H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.006 · Cited by 17
Glucose variability predicts 6-month mortality in patients hospitalized with acute heart failure
Cunha, F. M., Cidade-Rodrigues, C., Elias, C., Oliveira, D., Bettencourt, P., & Lourenço, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02719-7 · Cited by 21
“Nevertheless, intervention studies in patients with DM aiming to attenuate postprandial hyperglycaemia found no differences in cardiovascular outcomes [46] or markers of cardiometabolic risk [47].”
BackgroundMultiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.03.005 · Cited by 19
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 37
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
Diet and glycaemia: the markers and their meaning. A report of the Unilever Nutrition Workshop
Alssema, M., Boers, H. M., Ceriello, A., Kilpatrick, E. S., Mela, D. J., Priebe, M. G., Schrauwen, P., Wolffenbuttel, B. H. R., & Pfeiffer, A. F. H. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514003547 · Cited by 20
“lar effects of lowering postprandial glucose as such, these trials have also shown that in diabetic patients, it is difficult to achieve the target for postprandial glucose lowering((64,65)).”
BackgroundScholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
“2008] and HEART2D [Raz et al. 2009] in combination with the data of UKPDS [Turner et al.”
ResultGlycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Christiansen, J. S., Liebl, A., Davidson, J. A., Ligthelm, R. J., & Halimi, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01144.x · Cited by 16
“In the recent HEART2D study [7], prandial or basal insulin therapy resulted in no difference in risk of future cardiovascular events in patients”
BackgroundOptimal Insulin Treatment in Type 2 Diabetes
Roden, M. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908706 · Cited by 19
Prediabetes and major adverse cardiac events after acute coronary syndrome: An overestimated concept
Behnoush, A. H., Maleki, S., Arzhangzadeh, A., Khalaji, A., Pezeshki, P. S., Vaziri, Z., Esmaeili, Z., Ebrahimi, P., Ashraf, H., Masoudkabir, F., et al. (2024) · Clinical Cardiology · doi:10.1002/clc.24262 · Cited by 16
de Almeida-Pititto, B., Ribeiro‐Filho, F. F., Lotufo, P. A., Benseñor, I. M., & Ferreira, S. R. G. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.021 · Cited by 17
Lundby‐Christensen, L., Vaag, A. A., Tarnow, L., Almdal, T., Lund, S. S., Wetterslev, J., Gluud, C. N., Boesgaard, T. W., Wiinberg, N., Perrild, H., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008377 · Cited by 16
Giménez, M., Gilabert, R., Lara, M., & Conget, I. (2010) · Diabetes and Vascular Disease Research · doi:10.1177/1479164110388674 · Cited by 17
“However, at least in high-risk subjects, it has not been shown that treating postprandial hyperglycaemic peaks has any beneficial effect in reducing cardiovascular events in diabetic patients.(30) Despite the assumption that glucose variability is greater than in T2D, there is still controversial data concerning wheth…”
BackgroundIntensive Glycemic Control and Cardiovascular Disease: Are There Patients Who May Benefit?
Chokrungvaranon, N., Deer, J., & Reaven, P. D. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2501 · Cited by 15
Peng, C., Yue-an, C., Tian, Y., Zhang, W.-L., Xia, J., & Yang, L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.010 · Cited by 15
Yoo, S., Chin, S. O., Lee, S.-A., & Koh, G. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.3.352 · Cited by 15
Ogiso, K., Shayo, S. C., Kawade, S., Hashiguchi, H., Deguchi, T., & Nishio, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263080 · Cited by 17
“Both prandial (rapid-acting) insulin and nateglinide, which are agents that target postprandial hyperglycemia, do not reduce CVD events (the HEART2D and NAVIGATOR trials) [10,11].”
BackgroundKawano, Y., Takemoto, M., Mito, T., Morisaki, H., Tanaka, A., Sakaki, Y., Matsuo, A., Abe, K., Hida, S., Mukae, K., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.008 · Cited by 16
“There are many clinical trials that could not prevent cardiovascular events, including CAD and cerebrovascular infarctions, as the primary endpoint in the interventional examinations for T2DM after many years from the onset [15–21].”
BackgroundDevoting attention to glucose variability and hypoglycaemia in type 2 diabetes
Rutter, M. K. (2017) · Diabetologia · doi:10.1007/s00125-017-4421-1 · Cited by 15
“This lack of ongoing trials might reflect the practical issues of performing such trials, a lack of interest from pharmaceutical companies and/or the disappointing results from a previous trial targeting postprandial hyperglycaemia [18].”
ResultYoon, S.-Y., Kim, J. S., Ko, G. J., Choi, Y., Moon, J.-Y., Jeong, K. H., & Hwang, H. S. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.23.098 · Cited by 14
“Fasting blood glucose (FBG) level is a representative marker of glucose control status, and it is widely used along with glycated hemoglobin (HbA1c) to assess the risk of clinically important complications [11,12].”
BackgroundStrojek, K., Raz, I., Jermendy, G., Gitt, A. K., Liu, R., Zhang, Q., Jacober, S. J., & Miličević, Z. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1962 · Cited by 10
“mographic characteristics are reported elsewhere (8).”
BackgroundResultInfluentialSelf-citationIntermittent high glucose promotes expression of proinflammatory cytokines in monocytes
Yang, L., Wen-bo, Q., Lv, X., You-lun, F., & Zhang, T. (2010) · Inflammation Research · doi:10.1007/s00011-010-0279-0 · Cited by 14
“However, other studies failed to show that postprandial hyperglycemia was more of a risk factor for cardiovascular diseases than fasting plasma glucose or HbA1c [6, 7].”
BackgroundSmolen, H. J., Murphy, D. R., Gahn, J. C., Yu, X., & Curtis, B. H. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.9.968 · Cited by 14
Nakajima, K., Mita, T., Osonoi, Y., Azuma, K., Takasu, T., Fujitani, Y., & Watada, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/406394 · Cited by 12
“remain controversial [7], the studies cited above suggest that glucose fluctuation could adversely affect the progression of atherosclerosis.”
Corrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.12.002 · Cited by 18
Fumisawa, Y., Funase, Y., Yamashita, K., Yamauchi, K., Miyamoto, T., Tsunemoto, H., Sakurai, S., & Aizawa, T. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13334 · Cited by 9
Kohnert, K., Heinke, P., Vogt, L., Zander, E., Fritzsche, G., Augstein, P., & Salzsieder, E. (2011) · Journal of Endocrinology and Metabolism · doi:10.4021/jem.v1i2.21 · Cited by 11
“basal glycemia strategy for future cardiovascular events [6].”
BackgroundSakai, T., Aoyama, K., Inazumi, K., Kikuchi, R., Sato, Y., Tada, A., Hirata, T., & Morimoto, J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107962 · Cited by 10
Liu, Y., Fu, H., Wang, Y., Sun, J., Zhang, R., Zhong, Y., Yang, T., Han, Y. T., Xiang, Y., Yuan, B., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1546164 · Cited by 12
Garber, A. J. (2011) · PubMed · Cited by 11
Humalog (lispro) for type 2 diabetes
Esposito, K., Capuano, A., & Giugliano, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.728584 · Cited by 12
“We included randomized controlled trials (RCTs), which included at least one arm evaluating insulin lispro in type 2 diabetes.”
BackgroundInfluentialFreeman, J. S. (2010) · PubMed · Cited by 10
Diagnóstico y control de la diabetes mellitus tipo 2
Espino, J. D. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70002-0 · Cited by 18
Hoogwerf, B. J., Lincoff, A. M., Rodríguez, Á., Chen, L., & Qu, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0393-6 · Cited by 10
“Heart 2D assessed the effects of prandial insulin therapy versus basal insulin on CV events and did not show a difference [36], except in a subset of patients over the age of 65 [37].”
MethodCorrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.06.015 · Cited by 18
Metadata
- Authors
- Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
- Affiliations
- Hadassah Medical Center (IL)
- Emory University (US)
- Medical University of Silesia (PL)
- Medical University of Białystok (PL)
- Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
- Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
- Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
- Eli Lilly (United States) (US)
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 381-386
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646013
- OpenAlex
- W2172111876
- Cited by
- 351
- References
- 26
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
- FWCI
- 29.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
- MeSH terms
- Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.